Captopril reversed the PLS poor-prognosis status with significantly decreased expression of the poor-prognosis PLS genes associated with HCC risk similarly to erlotinib, which is the EGFR inhibitor (Figure 7E). Here, EGFR is linked to hepatocellular carcinoma.